Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab exploratory FRI study in severe eosinophilic asthma
NL-OMON26915Not yet recruiting
- Sponsor
- CIRO
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of benralizumab in eosinophilic asthma (EA), sponsored by CIRO. Primary endpoint: Effect and onset of benralizumab on Functional Respiratory Imaging parameters. Planned start Mar 2021; status: not yet recruiting.
02
Drugs
benralizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NL-OMON26915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26915.